Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

The 3 Best International ETFs to Consider for Diversification

By Josh Enomoto, InvestorPlace Contributor

While some general truth exists in the assertion that American investors should stick with U.S.-based investments for familiarity and performance reasons, the best international ETFs…

3 Cutting-Edge Biotech Stocks for the Bold Investor

By Josh Enomoto, InvestorPlace Contributor

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative…

7 Must-Buy Stocks That Are on Ridiculous Discount Now

By Josh Enomoto, InvestorPlace Contributor

Given that this may be the year of artificial intelligence, it’s no surprise that while certain enterprises have hogged the spotlight, astute investors also enjoy…

Analyst Upgrades: 7 Stocks That Just Got the Pros’ Attention

By Josh Enomoto, InvestorPlace Contributor

While investors should always conduct their own research and consider various viewpoints, targeting stocks with analyst upgrades offers an excellent starting point. For one thing,…

Why Is Tenax Therapeutics (TENX) Stock Up 300% Today?

By Josh Enomoto, InvestorPlace Contributor

Although Tenax Therapeutics has received a green light for its investigational drug, investors should exercise caution with TENX stock.

Load More